Overview

2009 Cancer Summit: Lung, Head & Neck, Breast, and Gastrointestinal and Colorectal Cancers

Hilton Oceanfront Resort, 23 Ocean Lane, Hilton Head Island, SC - July 23-25, 2009

Program Directors:

   Chandra P. Belani, MD,

Miriam Beckner Distinguished Professor of Medicine, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Deputy Director, Penn State Cancer Institute, Hershey, PA

   Mark Pegram, MD,

Sylvester Distinguished Professor of Medicine, University of Miami Miller School of Medicine, Director, Translational Research, Braman Breast Cancer Research Institute, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL

   Axel Grothey, MD,

Professor of Oncology and Consultant, Mayo Clinic, Rochester, MN

Target Audience

This symposium is directed primarily to medical oncologists, radiation oncologists, surgical oncologists, researchers, pharmacists, registered nurses, nurse practitioners, and physician assistants interested in new developments for treatment of solid tumors such as lung cancer, head & neck cancers, breast cancer, gastrointestinal cancers, and colorectal cancer. No specific skill or knowledge other than a basic training in oncology is required for successful participation in this activity. Fellows are also invited to attend.

Statement of Need/Program Overview

This program is intended to facilitate interaction among medical oncologists, radiation oncologists, surgical oncologists, nurses, pharmacists, physician assistants, and nurse practitioners interested in development of novel therapeutics for treatment of solid tumors such as lung, head & neck cancers, breast cancer, and gastrointestinal/colorectal cancers. This symposium will present data of most promising emerging agents currently in development for the treatment. There will be in-depth discussion of targeted therapies for solid tumors.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and International Cancer Network. PIM is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a maximum of 15.25 hours of AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

    Accreditation Statement

    Credit Designation

Postgraduate Institute for Medicine designates each day of this continuing education activity for credit from the Accreditation Council for Pharmacy Education as follows: Thursday, July 23, 2009: 5.3 contact hour(s) (0.53 CEUs) - Universal Activity Number 809-999-09-063-LO1-P Friday, July 24, 2009: 4.8 contact hour(s) (0.48 CEUs) - Universal Activity Number 809-999-09-064-LO1-P; Saturday, July 25, 2009: 5.3 contact hour(s) (0.53 CEUs) - Universal Activity Number 809-999-09-065-LO1-P).

Nursing Continuing Education

    Purpose

The purpose of this activity is to assist oncology healthcare professionals in the diagnosis, treatment, and management of patients with lung, head & neck, breast, and gastrointestinal/colorectal cancers.

    Credit Designation

This educational activity for 15.4 contact hours is provided by Postgraduate Institute for Medicine (PIM).

    Accreditation Statements

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within three weeks (if applicable).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

.Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Roberta Granny prior to the live event at 410-491-7492.

Jointly sponsored by International Cancer Network and Postgraduate Institute for Medicine

This Activity is supported by educational grants from:

Abraxis Oncology
Genentech BioOncology
Bristol-Myers Squibb/ImClone Systems
Abbott Pharmaceuticals